Search Result

Results for "

Nonalcoholic steatohepatitis (NASH)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (18) Apical Sodium-Dependent Bile Acid Transporter (1) Autophagy (3) Caspase (1) CCR (1) Cytochrome P450 (2) Dipeptidyl Peptidase (1) Endogenous Metabolite (3) FXR (8) GCGR (2) GLP Receptor (2) HCV (1) HIV (1) Insulin Receptor (1) Isotope-Labeled Compounds (1) Keap1-Nrf2 (1) Ketohexokinase (2) Mitochondrial Metabolism (1) Phosphatase (1) PPAR (2) RAR/RXR (1) SphK (1) Stearoyl-CoA Desaturase (SCD) (1) TAM Receptor (1) Thyroid Hormone Receptor (2)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (15) Metabolic Disease (43) Neurological Disease (1)

By Targets:

17β-HSD (18)

Apical Sodium-Dependent Bile Acid Transporter (1)

Autophagy (3)

Caspase (1)

CCR (1)

Cytochrome P450 (2)

Dipeptidyl Peptidase (1)

Endogenous Metabolite (3)

FXR (8)

GCGR (2)

GLP Receptor (2)

HCV (1)

HIV (1)

Insulin Receptor (1)

Isotope-Labeled Compounds (1)

Keap1-Nrf2 (1)

Ketohexokinase (2)

Mitochondrial Metabolism (1)

Phosphatase (1)

PPAR (2)

RAR/RXR (1)

SphK (1)

Stearoyl-CoA Desaturase (SCD) (1)

TAM Receptor (1)

Thyroid Hormone Receptor (2)

By Research Areas:

Cancer (4)

Cardiovascular Disease (1)

Infection (2)

Inflammation/Immunology (15)

Metabolic Disease (43)

Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149831

ZLY28	FXR	Metabolic Disease
ZLY28 is the first-in-class intestinal restricted and orally active FXR and FABP1 dual modulator. ZLY28 also is a novel anti-NASH agent. ZLY28 can be used for the research of nonalcoholic steatohepatitis (NASH) .

HY-109096

Nidufexor LMB763	FXR Autophagy	Inflammation/Immunology
Nidufexor (LMB763) is an orally-available farnesoid X receptor (FXR) agonist for the research of nonalcoholic steatohepatitis (NASH) .

HY-19796

Icomidocholic acid 1 Publications Verification Aramchol; C20-FABAC	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
Icomidocholic acid (Aramchol) is a conjugate of cholic acid and arachidic acid that could inhibit stearoyl coenzyme A desaturase 1 (SCD1) activity. Icomidocholic acid has potential use in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) treatment .

HY-119039

RU-301	TAM Receptor	Inflammation/Immunology Cancer
RU-301 is a pan TAM inhibitor that blocks Gas6-induced TAM activation and tumorigenicity. RU-301 significantly reduces nonalcoholic steatohepatitis (NASH) fibrosis, along with attenuates ERK activation and TGFβ1 expression. RU-301 can be used in studies of cancer and nonalcoholic steatohepatitis .

HY-P6177

SGP8	Dipeptidyl Peptidase	Inflammation/Immunology
SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH) .

HY-163071

V023-9340	FXR	Metabolic Disease
V023-9340 is a potent FXR inhibitor with IC₅₀ of 4.27 μM that can be used in NASH (nonalcoholic steatohepatitis) research .

HY-163886

KHK-IN-5	Ketohexokinase	Metabolic Disease
KHK-IN-5 (Compound 18) is a KHK inhibitor. KHK-IN-5 can be used for the research of nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and type 2 diabetes (T2DM) .

HY-16521

VX-166	Caspase	Inflammation/Immunology
VX-166, a pan caspase inhibitor, can be used for the research of Non- Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other diseases involving fibrosis, steatosis, or inflammation of the liver .

HY-137922

SHS4121705	Others	Metabolic Disease
SHS4121705 is an orally effective mitochondrial uncoupling agent with an IC₅₀ of 4.3 μM in L6 myoblasts. SHS4121705 can be used in the study of non-alcoholic steatohepatitis (NASH) .

HY-101190

Volixibat SHP626; LUM002	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH) .

HY-116374A

Glycolithocholic acid sodium Lithocholylglycine sodium	Others	Metabolic Disease
Glycolithocholic acid (Lithocholylglycine) sodium is the sodium salt of Glycolithocholic acid. Glycolithocholic acid is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-116374

Glycolithocholic acid Lithocholylglycine	Endogenous Metabolite	Inflammation/Immunology
Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-153114

HEC96719	FXR	Inflammation/Immunology
HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC₅₀ values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis .

HY-161979

HSD17B13-IN-103	17β-HSD	Cancer
HSD17B13-IN-103 (Compound 44) is a HSD17B13 inhibitor. HSD17B13-IN-103 can be used in the study of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .

HY-155525

Anti-NASH agent 1	PPAR	Metabolic Disease Inflammation/Immunology
Anti-NASH agent 1 (compound 3d)，a derivative of Elafibranor (HY-16737)，is a potent agonist of PPAR-α/δ，targeting to nonalcoholic steatohepatitis (NASH). Anti-NASH agent 1 (3-10 mg/kg; 4 weeks) improves hyperlipidemia，liver fat degeneration and liver inflammation in Methionine-choline deficiency (MCD) induced NASH mice model. Anti-NASH agent 1 shows low liver toxicity and potent liver protection effect .

HY-113111

11,12-DiHETrE	Endogenous Metabolite	Inflammation/Immunology
11,12-DiHETrE, an endogenous metabolite, is a Cytochrome P450 (P450) eicosanoid. 11,12-DiHETrE can be used for preterm labor research. 11,12-DiHETrE can be used as a single biomarker for differentiating NAFL (nonalcoholic fatty liver) from NASH (nonalcoholic steatohepatitis) .

HY-149893

MGAT2-IN-4	Others	Metabolic Disease
MGAT2-IN-4 (compound 33) is an inhibitor of monoacylglycerol transferase 2 (MGAT2), with liver metabolic stability. MGAT2-IN-4 can be used for research on obesity, diabetes and non-alcoholic steatohepatitis (NASH) .

HY-109083

Cilofexor Maximum Cited Publications 10 Publications Verification GS-9674	FXR Autophagy	Inflammation/Immunology
Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC₅₀ of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research .

HY-153476

GIP/GLP-1 dual receptor agonist-1	GCGR	Metabolic Disease
GIP/GLP-1 dual receptor agonist-1 (compound 4) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) .

HY-116374S

Glycolithocholic acid-d4 Lithocholylglycine-d4	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Glycolithocholic acid-d₄ is the deuterium labeled Glycolithocholic acid. Glycolithocholic acid, an endogenous metabolite, is a glycine-conjugated secondary bile acid and can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) [1][2][3][4].

HY-146997

TRβ agonist 1	Thyroid Hormone Receptor	Metabolic Disease
TRβ agonist 1 is a selective and mutation-sensitive thyroid hormone receptor β (TRβ) agonist, with an EC₅₀ value of 21 nM. TRβ agonist 1 can be used for researching dyslipidemia, nonalcoholic steatohepatitis (NASH), and resistance to thyroid hormone (RTH) .

HY-156065

S217879	Keap1-Nrf2	Metabolic Disease
S217879 is a highly potent and selective NRF2 activator. S217879 disrupts the KEAP1-NRF2 interaction leading to robust NRF2 pathway activation. S217879 can be used for non-alcoholic steatohepatitis (NASH) research .

HY-151481

FXR antagonist 1	FXR	Metabolic Disease
FXR antagonist 1 (compound F6) is an orally active and selective intestinal FXR antagonist (IC₅₀=2.1 μM). FXR antagonist 1 selectively inhibits intestinal FXR signalling through antagonism of intestinal FXR and feedback activation of hepatic FXR to improve hepatic steatosis, inflammation and fibrosis in NASH (nonalcoholic steatohepatitis) models. FXR antagonist 1 can be used in NASH studies .

HY-148926

HSD17B13-IN-1	17β-HSD	Metabolic Disease
HSD17B13-IN-1 (compound 2) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-1? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-157663

HSD17B13-IN-36	17β-HSD	Metabolic Disease
HSD17B13-IN-36 (compound 116) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-36? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-161225

HSD17B13-IN-40	17β-HSD	Metabolic Disease
HSD17B13-IN-40 (compound 6) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-40? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-161226

HSD17B13-IN-42	17β-HSD	Metabolic Disease
HSD17B13-IN-42 (compound 10)? is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-42? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-163242

HSD17B13-IN-28	17β-HSD	Metabolic Disease
HSD17B13-IN-28 (compound? 47) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-28? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-163244

HSD17B13-IN-30	17β-HSD	Metabolic Disease
HSD17B13-IN-30 (compound 64) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-30? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-163247

HSD17B13-IN-35	17β-HSD	Metabolic Disease
HSD17B13-IN-35 (compound 76) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM? estradiol? as substrates. HSD17B13-IN-35? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-108022

Azemiglitazone MSDC-0602	Mitochondrial Metabolism PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
Azemiglitazone (MSDC-0602) is an orally active thiazolidinedione (TZD) -like molecule, which binds to PPARγ with low binding and activating affinity. Azemiglitazone inhibits mitochondrial pyruvate carrier (MPC), which inhibits Alzheimer’s disease and diminishes nonalcoholic steatohepatitis (NASH) caused liver injury .

HY-P99697

Leronlimab PRO 140	CCR HIV	Infection Cancer
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .

HY-150787

BMS-986339	FXR Cytochrome P450	Metabolic Disease
BMS-986339 is an orally active, potent FXR agonist. BMS-986339 forms H-bond with His298 and ASN287 residues. BMS-986339 can be used in the research of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH), anti-fibrosis .

HY-147246

Berberine ursodeoxycholate HTD1801; BUDCA	Others	Metabolic Disease
Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes .

HY-148814

BI-3231	17β-HSD	Metabolic Disease
BI 3231 is a potent and selective hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor, with IC₅₀s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases .

HY-162223

HSD17B13-IN-97	17β-HSD	Metabolic Disease
HSD17B13-IN-97 (compound 4) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor with an IC₅₀ value of ≤0.1 µM. HSD17B13-IN-97 has the potential for the research of Nonalcoholic fatty liver diseases (NAFLDs), nonalcoholic steatohepatitis (NASH) or or drug induced liver injury (DILI) .

HY-161217

HSD17B13-IN-16	17β-HSD	Metabolic Disease
HSD17B13-IN-16 (compound 8) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-16? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-161218

HSD17B13-IN-17	17β-HSD	Metabolic Disease
HSD17B13-IN-17 (compound 9) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-17? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-161219

HSD17B13-IN-18	17β-HSD	Metabolic Disease
HSD17B13-IN-18 (compound 13) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-18? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-161220

HSD17B13-IN-19	17β-HSD	Metabolic Disease
HSD17B13-IN-19 (compound 16) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-19? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-161221

HSD17B13-IN-21	17β-HSD	Metabolic Disease
HSD17B13-IN-21 (compound 17) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-21? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-161222

HSD17B13-IN-23	17β-HSD	Metabolic Disease
HSD17B13-IN-23 (compound 18) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-23? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-161223

HSD17B13-IN-27	17β-HSD	Metabolic Disease
HSD17B13-IN-27 (compound 30) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM and ?＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-27? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-161224

HSD17B13-IN-31	17β-HSD	Metabolic Disease
HSD17B13-IN-31 (compound 32) is a ppotent inhibitor of hydroxysteroid 17?-dehydrogenase 13 (HSD17B13), with the IC₅₀ of ＜ 0.1 μM and? ＜ 1 μM estradiol and Leukotriene B3 as substrates, respectively. HSD17B13-IN-31? plays an important role in nonalcoholic fatty liver diseases (NAFLDs) including NASH (nonalcoholic steatohepatitis) .

HY-142917

THR-β agonist 4	Others	Metabolic Disease
THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021143706A1, compound 72) .

HY-143613

THR-β agonist 2	Others	Metabolic Disease
THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3) .

HY-143614

THR-β agonist 3	Others	Metabolic Disease
THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021129827A1, compound 6) .

HY-P3463

Beinaglutide GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

HY-134988

EDP-305	FXR Phosphatase Cytochrome P450	Inflammation/Immunology
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC₅₀ values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .

HY-149218

THR-β agonist 6	Thyroid Hormone Receptor	Metabolic Disease Inflammation/Immunology
THR-β agonist 6 is an orally active, selective thyroid hormone receptor β (THR-β) agonist with EC₅₀s of 0.03 μM and 0.22 μM for THR-β and THR-α, respectively. THR-β agonist 6 exhibits an xcellent liver-to-serum ratio of 93:1 in mice. THR-β agonist 6 has the potential for nonalcoholic steatohepatitis (NASH) research .

Cat. No.	Product Name

HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

3,225 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 3,225 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

Cat. No.	Product Name	Target	Research Area

HY-P3463

Beinaglutide GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

HY-P10302A

GLP-1R/GIPR agonist-1 (soduim)	GLP Receptor	Metabolic Disease
GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC₅₀ is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC₅₀ is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P6177

SGP8	Dipeptidyl Peptidase	Inflammation/Immunology
SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH) .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

Cat. No.	Product Name	Target	Research Area

HY-P99428

Aldafermin NGM282	Inhibitory Antibodies	Metabolic Disease
Aldafermin (NGM282) is an analog of fibroblast growth factor 19. Aldafermin can be used for the research of nonalcoholic steatohepatitis (NASH) .